Remote care technology and drug price limits garnered the most votes for having the biggest effect on the cost and delivery of U.S. healthcare.
The COVID-19 pandemic continues to scramble American healthcare, but it is already clear that telehealth and other forms of remote care are going to be lasting consequences.
That observation is reflected in results from our State of the Industry survey, which we revised this year to ask questions that look to the year ahead rather than assessing the year gone by. The survey had 100 respondents.
When we asked respondents to pick two technology developments that would have the biggest effect on the cost and development of healthcare in 2022, 66% picked remote care technologies, far outpacing the precision medicine, which was picked by 35% of the respondents, and at-home hospital care, which was picked by 29%.
We also asked about policy and political developments. It was closer race. Drug price limits (51%) and expansion of Medicare benefits (49%) finished neck and neck. Despite all the discussion, addressing social determinants of health (14%) and healthcare disparities (12%) ranked far lower.
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.
Read More